Study Groups

A meta-analysis of individual patient data (IPD) to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on artemether and lumefantrine pharmacokinetics (PK). The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of artemether-lumefantrine (AL) in HIV-infected patients.

Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of piperaquine in pregnant women.

Determining the effects of pregnancy on piperaquine pharmacokinetics. The analysis aims to contribute evidence needed to inform recommendations on the use and optimal dosing of piperaquine in pregnant women.

This Study Group aims to bring together and explore the latest evidence on the prevalence of molecular markers associated with antimalarial drug resistance in West African Countries.

This Study Group will explore the link between P. vivax recurrence and prior P. falciparum treatment, including increased risk of vivax parasitaemia due to acute malaria infection.

The Subpatent Malaria and Pregnancy Outcome Study Group aims to explore the relationship between subpatent Plasmodium falciparum malaria infection and pregnancy outcome

The sulphadoxine-pyrimethamine (SP) resistance Data Access Group’s aim is to provide maps and open access to the most recent data on molecular markers of SP resistance to help policy makers make informed decisions with regard to use of SP for intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of malaria in pregnancy, specifically intermittent screening and treatment (ISTp), with an artemisinin-based combination therapy (ACT).

Assessing the efficacy of a range of antimalarials used for the treatment of P. falciparum malaria in all trimesters of pregnancy in Africa and Asia

The MiP Treatment Efficacy Study Group was formed in July 2016, with a call to interested researchers with relevant data sets.

The Sulphadoxine-Pyrimethamine (SP) resistance Study Group’s aim is to provide open access to, and establish maps with, the most recent data on SP resistance to inform policy decisions on the clinical effectiveness of SP when provided as part of intermittent preventive treatment of malaria in pregnancy (IPTp) or seasonal malaria chemoprevention (SMC).

The Alternative MiP Prevention Strategies (AMPS) Study Group’s aim is to determine the safety and efficacy of novel strategies for the control of malaria in pregnancy including intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine (DP) and intermittent screening and treatment (ISTp) with DP or artemether-lumefantrine (AL).

The First Trimester Safety of ACTs Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use of artemisinin combination therapies in the first trimester of pregnancy.

The Piperaquine Safety Study Group’s aim is to establish the evidence-base and safety profile to inform decision-making on the use and optimal dosing of dihydroartemisinin-piperaquine in all key target populations.

The study group call for contributors opened in June 2016 with a first scoping meeting held in July. Data collection is planned to close by end of 2016, with analysis due in 2018-2019.

An analysis of pooled individual patient data to determine the effect of antiretroviral (ARV) drug-drug interactions and HIV disease on lumefantrine pharmacokinetics (and pharmacodynamics).

This study group has just opened for data collection. If you have any data you would like to share, or if you would like to participate in the project, please contact pharmacology@wwarn.org.

A pooled analysis assessing the effect of mg/kg dosing strategies on the risk of treatment failure in patients treated with the currently recommended dose of artesunate-mefloquine (AS-MQ).

Research groups with relevant data have been contacted with data collection and curation still ongoing. Analysis will start in late 2016 and drafting publication in expected in 2018.

Modelling the protective effect of Artesunate-Amodiaquine (AS-AQ)

A pooled analysis to assess the post-treatment prophylactic effect of artesunate-amodiaquine (AS-AQ). The group is quantifying the duration of post-treatment prophylaxis mediated by AS-AQ and how it depends on host factors such as .

The Study Group closed in January 2014. The AS-AQ Post-Treatment Prophylaxis Study Group manuscript is under review at BMC Medicine. 

Development of statistical methods to infer the relationship between the percentage of resistant infections, parasite clearance half-life and the proportion of treated individuals still positive on days one, two and three of treatment